Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib
CONCLUSIONS: In our cohort of patients with mRCC treated with sunitinib, low LMR (>3) and high PLR (>150) were associated with shorter PFS. Macrocytosis was not prognostic.PMID:34296630 | DOI:10.1177/03008916211033905 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Elena Bolzacchini Monica Giordano Lorenza Bert ù Marco Bregni Olga Nigro Luca Galli Andrea Antonuzzo Salvatore Artale Sabrina Barzaghi Marco Danova Martina Torchio Graziella Pinotti Francesco Dentali Source Type: research

Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases
CONCLUSIONS: The findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC.PMID:34296632 | DOI:10.1177/03008916211033353 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: JieLang Li Ting Chen Feng Bi Yu Yang Source Type: research

Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia
CONCLUSION: L-DNR proved to be an effective drug within a multiagent approach, which shows a favorable overall profile, as well as similar adverse events when compared with IDA in HR-ALL. Patients with E2A-PBX1 are much more sensitive to L-DNR than IDA. Despite some progress made, outcomes in MLL rearrangement or P53 mutation carriers remain unsatisfactory, and intensive treatment will be critical.PMID:34296648 | DOI:10.1177/03008916211032724 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Qi Zhang Chun-Hong Zhang Zhen-Dong Wang Dong Wang Source Type: research

Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib
CONCLUSIONS: In our cohort of patients with mRCC treated with sunitinib, low LMR (>3) and high PLR (>150) were associated with shorter PFS. Macrocytosis was not prognostic.PMID:34296630 | DOI:10.1177/03008916211033905 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Elena Bolzacchini Monica Giordano Lorenza Bert ù Marco Bregni Olga Nigro Luca Galli Andrea Antonuzzo Salvatore Artale Sabrina Barzaghi Marco Danova Martina Torchio Graziella Pinotti Francesco Dentali Source Type: research

Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases
CONCLUSIONS: The findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC.PMID:34296632 | DOI:10.1177/03008916211033353 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: JieLang Li Ting Chen Feng Bi Yu Yang Source Type: research

Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia
CONCLUSION: L-DNR proved to be an effective drug within a multiagent approach, which shows a favorable overall profile, as well as similar adverse events when compared with IDA in HR-ALL. Patients with E2A-PBX1 are much more sensitive to L-DNR than IDA. Despite some progress made, outcomes in MLL rearrangement or P53 mutation carriers remain unsatisfactory, and intensive treatment will be critical.PMID:34296648 | DOI:10.1177/03008916211032724 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Qi Zhang Chun-Hong Zhang Zhen-Dong Wang Dong Wang Source Type: research

Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib
CONCLUSIONS: In our cohort of patients with mRCC treated with sunitinib, low LMR (>3) and high PLR (>150) were associated with shorter PFS. Macrocytosis was not prognostic.PMID:34296630 | DOI:10.1177/03008916211033905 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Elena Bolzacchini Monica Giordano Lorenza Bert ù Marco Bregni Olga Nigro Luca Galli Andrea Antonuzzo Salvatore Artale Sabrina Barzaghi Marco Danova Martina Torchio Graziella Pinotti Francesco Dentali Source Type: research

Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases
CONCLUSIONS: The findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC.PMID:34296632 | DOI:10.1177/03008916211033353 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: JieLang Li Ting Chen Feng Bi Yu Yang Source Type: research

Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia
CONCLUSION: L-DNR proved to be an effective drug within a multiagent approach, which shows a favorable overall profile, as well as similar adverse events when compared with IDA in HR-ALL. Patients with E2A-PBX1 are much more sensitive to L-DNR than IDA. Despite some progress made, outcomes in MLL rearrangement or P53 mutation carriers remain unsatisfactory, and intensive treatment will be critical.PMID:34296648 | DOI:10.1177/03008916211032724 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Qi Zhang Chun-Hong Zhang Zhen-Dong Wang Dong Wang Source Type: research

Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib
CONCLUSIONS: In our cohort of patients with mRCC treated with sunitinib, low LMR (>3) and high PLR (>150) were associated with shorter PFS. Macrocytosis was not prognostic.PMID:34296630 | DOI:10.1177/03008916211033905 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Elena Bolzacchini Monica Giordano Lorenza Bert ù Marco Bregni Olga Nigro Luca Galli Andrea Antonuzzo Salvatore Artale Sabrina Barzaghi Marco Danova Martina Torchio Graziella Pinotti Francesco Dentali Source Type: research

Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases
CONCLUSIONS: The findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC.PMID:34296632 | DOI:10.1177/03008916211033353 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: JieLang Li Ting Chen Feng Bi Yu Yang Source Type: research

Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia
CONCLUSION: L-DNR proved to be an effective drug within a multiagent approach, which shows a favorable overall profile, as well as similar adverse events when compared with IDA in HR-ALL. Patients with E2A-PBX1 are much more sensitive to L-DNR than IDA. Despite some progress made, outcomes in MLL rearrangement or P53 mutation carriers remain unsatisfactory, and intensive treatment will be critical.PMID:34296648 | DOI:10.1177/03008916211032724 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Qi Zhang Chun-Hong Zhang Zhen-Dong Wang Dong Wang Source Type: research

Prognostic role of hematologic parameters of metastatic renal cell carcinoma treated with sunitinib
CONCLUSIONS: In our cohort of patients with mRCC treated with sunitinib, low LMR (>3) and high PLR (>150) were associated with shorter PFS. Macrocytosis was not prognostic.PMID:34296630 | DOI:10.1177/03008916211033905 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Elena Bolzacchini Monica Giordano Lorenza Bert ù Marco Bregni Olga Nigro Luca Galli Andrea Antonuzzo Salvatore Artale Sabrina Barzaghi Marco Danova Martina Torchio Graziella Pinotti Francesco Dentali Source Type: research

Efficacy of lenvatinib plus pembrolizumab in hepatocellular carcinoma with metachronous lung metastasis: a report of two cases
CONCLUSIONS: The findings of the current study and recently published data indicate lung metastasis as a potential clinical therapeutic indicator for efficacy of immunotherapy against HCC.PMID:34296632 | DOI:10.1177/03008916211033353 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: JieLang Li Ting Chen Feng Bi Yu Yang Source Type: research

Efficacy and safety of induction chemotherapy with daunorubicin or idarubicin in the treatment of an adult with acute lymphoblastic leukemia
CONCLUSION: L-DNR proved to be an effective drug within a multiagent approach, which shows a favorable overall profile, as well as similar adverse events when compared with IDA in HR-ALL. Patients with E2A-PBX1 are much more sensitive to L-DNR than IDA. Despite some progress made, outcomes in MLL rearrangement or P53 mutation carriers remain unsatisfactory, and intensive treatment will be critical.PMID:34296648 | DOI:10.1177/03008916211032724 (Source: Tumori)
Source: Tumori - July 23, 2021 Category: Cancer & Oncology Authors: Qi Zhang Chun-Hong Zhang Zhen-Dong Wang Dong Wang Source Type: research

Neoadjuvant chemotherapy followed by radical surgery in locally advanced vulvar carcinoma: a single-institution experience
CONCLUSION: NACT followed by surgery in locally advanced vulvar cancer is well tolerated and allows surgical modulation.PMID:34289750 | DOI:10.1177/03008916211027627 (Source: Tumori)
Source: Tumori - July 22, 2021 Category: Cancer & Oncology Authors: Adorni Marco Bazzurini Luca Lissoni Andrea Alberto Vecchione Francesca Negri Serena Grassi Tommaso Buda Alessandro Landoni Fabio Source Type: research

Neuroanatomical changes seen in MRI in patients with cerebral metastasized breast cancer after radiotherapy
CONCLUSIONS: These findings indicate that alterations in the volume of subcortical structures may act as a sensitive parameter when evaluating neuroanatomical changes and brain atrophy due to radiotherapy. Differences observed for patients who received STX and WBR, but not those treated with RS, need to be validated further.PMID:34256653 | DOI:10.1177/03008916211031301 (Source: Tumori)
Source: Tumori - July 14, 2021 Category: Cancer & Oncology Authors: Antonia Reibelt Michael Mayinger Kai J Borm Stephanie E Combs Marciana N Duma Source Type: research

Neobladder and ablative pelvic radiotherapy: still a taboo?
Tumori. 2021 Jul 8:3008916211031295. doi: 10.1177/03008916211031295. Online ahead of print.ABSTRACTThe presence of a neobladder constitutes a limitation for the radiation oncologist, as there is no clear evidence about its tolerance to radiotherapy (RT). The limited literature only concerns the conventional postoperative treatment in patients with bladder cancer after cystectomy. Here we report a case of a patient with neobladder who underwent a stereotactic RT for a pelvic recurrence of disease, with response to treatment and no toxicity to the neobladder. This case represents a promising example of the chance to perform ...
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Luca Bergamaschi Marianna Alessandra Gerardi Mattia Zaffaroni Matteo Augugliaro Sabrina Vigorito Elena Rondi Paolo Della Vigna Gianluca Varano Uberto Fumagalli Romario Roberto Biffi Edgardo Enrico Edoardo Picardi Annamaria Ferrari Barbara Alicja Jereczek- Source Type: research

MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach
CONCLUSION: The combination of clinical and radiomics features can provide information to predict behavior and prognosis of LACC and to make more accurate treatment decisions.PMID:34235995 | DOI:10.1177/03008916211014274 (Source: Tumori)
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Concetta Laliscia Angiolo Gadducci Roberto Mattioni Francesca Orlandi Sabina Giusti Amelia Barcellini Michela Gabelloni Riccardo Morganti Emanuele Neri Fabiola Paiar Source Type: research

Neobladder and ablative pelvic radiotherapy: still a taboo?
Tumori. 2021 Jul 8:3008916211031295. doi: 10.1177/03008916211031295. Online ahead of print.ABSTRACTThe presence of a neobladder constitutes a limitation for the radiation oncologist, as there is no clear evidence about its tolerance to radiotherapy (RT). The limited literature only concerns the conventional postoperative treatment in patients with bladder cancer after cystectomy. Here we report a case of a patient with neobladder who underwent a stereotactic RT for a pelvic recurrence of disease, with response to treatment and no toxicity to the neobladder. This case represents a promising example of the chance to perform ...
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Luca Bergamaschi Marianna Alessandra Gerardi Mattia Zaffaroni Matteo Augugliaro Sabrina Vigorito Elena Rondi Paolo Della Vigna Gianluca Varano Uberto Fumagalli Romario Roberto Biffi Edgardo Enrico Edoardo Picardi Annamaria Ferrari Barbara Alicja Jereczek- Source Type: research

MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach
CONCLUSION: The combination of clinical and radiomics features can provide information to predict behavior and prognosis of LACC and to make more accurate treatment decisions.PMID:34235995 | DOI:10.1177/03008916211014274 (Source: Tumori)
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Concetta Laliscia Angiolo Gadducci Roberto Mattioni Francesca Orlandi Sabina Giusti Amelia Barcellini Michela Gabelloni Riccardo Morganti Emanuele Neri Fabiola Paiar Source Type: research

Neobladder and ablative pelvic radiotherapy: still a taboo?
Tumori. 2021 Jul 8:3008916211031295. doi: 10.1177/03008916211031295. Online ahead of print.ABSTRACTThe presence of a neobladder constitutes a limitation for the radiation oncologist, as there is no clear evidence about its tolerance to radiotherapy (RT). The limited literature only concerns the conventional postoperative treatment in patients with bladder cancer after cystectomy. Here we report a case of a patient with neobladder who underwent a stereotactic RT for a pelvic recurrence of disease, with response to treatment and no toxicity to the neobladder. This case represents a promising example of the chance to perform ...
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Luca Bergamaschi Marianna Alessandra Gerardi Mattia Zaffaroni Matteo Augugliaro Sabrina Vigorito Elena Rondi Paolo Della Vigna Gianluca Varano Uberto Fumagalli Romario Roberto Biffi Edgardo Enrico Edoardo Picardi Annamaria Ferrari Barbara Alicja Jereczek- Source Type: research

MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach
CONCLUSION: The combination of clinical and radiomics features can provide information to predict behavior and prognosis of LACC and to make more accurate treatment decisions.PMID:34235995 | DOI:10.1177/03008916211014274 (Source: Tumori)
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Concetta Laliscia Angiolo Gadducci Roberto Mattioni Francesca Orlandi Sabina Giusti Amelia Barcellini Michela Gabelloni Riccardo Morganti Emanuele Neri Fabiola Paiar Source Type: research

Neobladder and ablative pelvic radiotherapy: still a taboo?
Tumori. 2021 Jul 8:3008916211031295. doi: 10.1177/03008916211031295. Online ahead of print.ABSTRACTThe presence of a neobladder constitutes a limitation for the radiation oncologist, as there is no clear evidence about its tolerance to radiotherapy (RT). The limited literature only concerns the conventional postoperative treatment in patients with bladder cancer after cystectomy. Here we report a case of a patient with neobladder who underwent a stereotactic RT for a pelvic recurrence of disease, with response to treatment and no toxicity to the neobladder. This case represents a promising example of the chance to perform ...
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Luca Bergamaschi Marianna Alessandra Gerardi Mattia Zaffaroni Matteo Augugliaro Sabrina Vigorito Elena Rondi Paolo Della Vigna Gianluca Varano Uberto Fumagalli Romario Roberto Biffi Edgardo Enrico Edoardo Picardi Annamaria Ferrari Barbara Alicja Jereczek- Source Type: research

MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach
CONCLUSION: The combination of clinical and radiomics features can provide information to predict behavior and prognosis of LACC and to make more accurate treatment decisions.PMID:34235995 | DOI:10.1177/03008916211014274 (Source: Tumori)
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Concetta Laliscia Angiolo Gadducci Roberto Mattioni Francesca Orlandi Sabina Giusti Amelia Barcellini Michela Gabelloni Riccardo Morganti Emanuele Neri Fabiola Paiar Source Type: research

Neobladder and ablative pelvic radiotherapy: still a taboo?
Tumori. 2021 Jul 8:3008916211031295. doi: 10.1177/03008916211031295. Online ahead of print.ABSTRACTThe presence of a neobladder constitutes a limitation for the radiation oncologist, as there is no clear evidence about its tolerance to radiotherapy (RT). The limited literature only concerns the conventional postoperative treatment in patients with bladder cancer after cystectomy. Here we report a case of a patient with neobladder who underwent a stereotactic RT for a pelvic recurrence of disease, with response to treatment and no toxicity to the neobladder. This case represents a promising example of the chance to perform ...
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Luca Bergamaschi Marianna Alessandra Gerardi Mattia Zaffaroni Matteo Augugliaro Sabrina Vigorito Elena Rondi Paolo Della Vigna Gianluca Varano Uberto Fumagalli Romario Roberto Biffi Edgardo Enrico Edoardo Picardi Annamaria Ferrari Barbara Alicja Jereczek- Source Type: research

MRI-based radiomics: promise for locally advanced cervical cancer treated with a tailored integrated therapeutic approach
CONCLUSION: The combination of clinical and radiomics features can provide information to predict behavior and prognosis of LACC and to make more accurate treatment decisions.PMID:34235995 | DOI:10.1177/03008916211014274 (Source: Tumori)
Source: Tumori - July 8, 2021 Category: Cancer & Oncology Authors: Concetta Laliscia Angiolo Gadducci Roberto Mattioni Francesca Orlandi Sabina Giusti Amelia Barcellini Michela Gabelloni Riccardo Morganti Emanuele Neri Fabiola Paiar Source Type: research

Complete response to immunotherapy in sinonasal undifferentiated carcinoma
We describe an impressive response in a young man previously treated with radiotherapy and chemotherapy and demolitive surgery who had metastatic bone and lung disease. We also report data on PD-L1, next-generation sequencing, and neutrophil/platelets ratio.PMID:34225515 | DOI:10.1177/03008916211026971 (Source: Tumori)
Source: Tumori - July 6, 2021 Category: Cancer & Oncology Authors: Nerina Denaro Marco Merlano Gianmauro Numico Ornella Garrone Paolo Bossi Source Type: research

Occult lymph node metastasis in patients with laryngeal cancer and relevant predicting factors: a single-center experience
CONCLUSION: Overall occult LNM is low (17.4%) in N0 laryngeal cancer, but the presence of LNM is a poor prognostic factor. Correct determination of the neck status and proper treatment is crucial. The incidence of LNM is very low in T1-T2 stages and well-differentiated tumors. The "wait and see" strategy may be applied in T1-T2 cases as well as selected T3 cases with well-differentiated tumors.PMID:34192979 | DOI:10.1177/03008916211026977 (Source: Tumori)
Source: Tumori - July 1, 2021 Category: Cancer & Oncology Authors: Ömer Bayır G ökhan Toptaş G üleser Saylam Turan Canmurat İzgi Ünsal Han Kemal Kesero ğlu İlker Akyıldız Mehmet Hakan Korkmaz Source Type: research

Fears, beliefs, and quality of life of patients with cancer vs the general population during the coronavirus disease 2019 (COVID-19) pandemic in Lombardy
Tumori. 2021 Jun 28:3008916211022848. doi: 10.1177/03008916211022848. Online ahead of print.ABSTRACTAIM: To understand how patients with cancer reacted to the coronavirus disease 2019 (COVID-19) pandemic and whether their quality of life (QoL) was affected.METHODS: In June 2020, 111 patients with cancer treated in the supportive care unit of a Comprehensive Cancer Center in Milan and 201 healthy controls from the general population were enrolled and assessed both quantitatively and qualitatively for fears and COVID-19-related beliefs as well as for QoL.RESULTS: Fear of COVID-19 was significantly lower among patients (41% v...
Source: Tumori - June 28, 2021 Category: Cancer & Oncology Authors: Carla Ida Ripamonti Giacomo Massa Daniela Insolvibile Mauro Guglielmo Guido Miccinesi Camillo Regalia Emanuela Saita Francesco Pagnini Source Type: research

Impact of innovation in oncology: more questions than answers
Tumori. 2021 Jun 27:3008916211027646. doi: 10.1177/03008916211027646. Online ahead of print.ABSTRACTOncology is going through the fastest innovation period in the history of medicine and a growing number of patients improve or experience increased chances of survival. The declining death rate, starting from 1991, resulted in 2.9 million deaths avoided in the United States so far. A growing prevalence of patients is observed in all Western countries. New cancer drug approvals between 2000 and 2016, linked to other diagnostic, surgical, and health care improvements, were significantly associated with death reduction for the ...
Source: Tumori - June 28, 2021 Category: Cancer & Oncology Authors: Gianpiero Fasola Maria Carla Barducci Giordano Beretta Source Type: research

Fears, beliefs, and quality of life of patients with cancer vs the general population during the coronavirus disease 2019 (COVID-19) pandemic in Lombardy
Tumori. 2021 Jun 28:3008916211022848. doi: 10.1177/03008916211022848. Online ahead of print.ABSTRACTAIM: To understand how patients with cancer reacted to the coronavirus disease 2019 (COVID-19) pandemic and whether their quality of life (QoL) was affected.METHODS: In June 2020, 111 patients with cancer treated in the supportive care unit of a Comprehensive Cancer Center in Milan and 201 healthy controls from the general population were enrolled and assessed both quantitatively and qualitatively for fears and COVID-19-related beliefs as well as for QoL.RESULTS: Fear of COVID-19 was significantly lower among patients (41% v...
Source: Tumori - June 28, 2021 Category: Cancer & Oncology Authors: Carla Ida Ripamonti Giacomo Massa Daniela Insolvibile Mauro Guglielmo Guido Miccinesi Camillo Regalia Emanuela Saita Francesco Pagnini Source Type: research

Impact of innovation in oncology: more questions than answers
Tumori. 2021 Jun 27:3008916211027646. doi: 10.1177/03008916211027646. Online ahead of print.ABSTRACTOncology is going through the fastest innovation period in the history of medicine and a growing number of patients improve or experience increased chances of survival. The declining death rate, starting from 1991, resulted in 2.9 million deaths avoided in the United States so far. A growing prevalence of patients is observed in all Western countries. New cancer drug approvals between 2000 and 2016, linked to other diagnostic, surgical, and health care improvements, were significantly associated with death reduction for the ...
Source: Tumori - June 28, 2021 Category: Cancer & Oncology Authors: Gianpiero Fasola Maria Carla Barducci Giordano Beretta Source Type: research

Fears, beliefs, and quality of life of patients with cancer vs the general population during the coronavirus disease 2019 (COVID-19) pandemic in Lombardy
Tumori. 2021 Jun 28:3008916211022848. doi: 10.1177/03008916211022848. Online ahead of print.ABSTRACTAIM: To understand how patients with cancer reacted to the coronavirus disease 2019 (COVID-19) pandemic and whether their quality of life (QoL) was affected.METHODS: In June 2020, 111 patients with cancer treated in the supportive care unit of a Comprehensive Cancer Center in Milan and 201 healthy controls from the general population were enrolled and assessed both quantitatively and qualitatively for fears and COVID-19-related beliefs as well as for QoL.RESULTS: Fear of COVID-19 was significantly lower among patients (41% v...
Source: Tumori - June 28, 2021 Category: Cancer & Oncology Authors: Carla Ida Ripamonti Giacomo Massa Daniela Insolvibile Mauro Guglielmo Guido Miccinesi Camillo Regalia Emanuela Saita Francesco Pagnini Source Type: research

Impact of innovation in oncology: more questions than answers
Tumori. 2021 Jun 27:3008916211027646. doi: 10.1177/03008916211027646. Online ahead of print.ABSTRACTOncology is going through the fastest innovation period in the history of medicine and a growing number of patients improve or experience increased chances of survival. The declining death rate, starting from 1991, resulted in 2.9 million deaths avoided in the United States so far. A growing prevalence of patients is observed in all Western countries. New cancer drug approvals between 2000 and 2016, linked to other diagnostic, surgical, and health care improvements, were significantly associated with death reduction for the ...
Source: Tumori - June 28, 2021 Category: Cancer & Oncology Authors: Gianpiero Fasola Maria Carla Barducci Giordano Beretta Source Type: research

Duvelisib as bridge to allotransplantation in refractory peripheral T-cell lymphoma with T-follicular helper phenotype: case report
CONCLUSIONS: Duvelisib should be further explored as a bridge to allotransplantation in patients with R/R PTCL, given the success and low toxicity in our patient.PMID:34167407 | DOI:10.1177/03008916211027219 (Source: Tumori)
Source: Tumori - June 25, 2021 Category: Cancer & Oncology Authors: Ginevra Lolli Beatrice Casadei Cinzia Pellegrini Lisa Argnani Federica Cocito Pier Luigi Zinzani Source Type: research

Prevention and management of acute esophageal toxicity during concomitant chemoradiotherapy for locally advanced lung cancer
CONCLUSIONS: Acute mild esophageal toxicity was confirmed to be a common side effect in this setting. No clinical-dosimetric parameter has been demonstrated to be effective in predicting acute esophageal toxicity. The use of Faringel Plus appears effective as a therapeutic and prophylactic tool to manage acute esophageal toxicity.PMID:34165018 | DOI:10.1177/03008916211025609 (Source: Tumori)
Source: Tumori - June 24, 2021 Category: Cancer & Oncology Authors: Paolo Borghetti Jessica Imbrescia Giulia Volpi Gianluca Costantino Gianluca Cossali Diana Greco Edoardo Pastorello Salvatore La Mattina Marco Lorenzo Bon ù Davide Tomasini Michela Buglione Source Type: research